| Document |
Document Title |
|
WO/2005/075426A1 |
The present invention relates to novel dipeptidyl peptidase IV (DPP-IV) inhibitors or general formula (1) useful for treating diabetes, non-insulin dependent diabetes mellitus, impaired glucose tolerance, inflammatory bowel disease, ulce...
|
|
WO/2005/075408A1 |
L-(-)-moprolol L-(+)-tartrate salt (2:1), method for preparing it and pharmaceutical composition comprising it.
|
|
WO/2005/072246A2 |
The present invention discloses methods of use of facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers, including, but not limited to, pharmaceutical uses of the polymers and oligomers as antimicrobial agents and as a...
|
|
WO/2005/070873A2 |
A composition that can be used as a component in auto clear coat and primer is disclosed. The composition comprises or is an alkoxylated amine having the formula of (A)[N(R1H)2]p including an isomer or mixture of isomers thereof. Also di...
|
|
WO/2005/070869A1 |
The present invention describes an improved catalyst and process for the selective hydrogenation of nitro aromatics, nitrosoaromatics and aromatic hydroxyl amines to their corresponding amines using gaseous hydrogen, in the presence of s...
|
|
WO/2005/071139A1 |
A composition of matter which can form a phosphorous containing surface on the surface of iron containing components in a combustion zone wherein hydrocarbons are being combusted, the composition containing nitrogen, phosphorous and an a...
|
|
WO/2005/068403A2 |
A method for the selective reduction of an aromatic compound. The present invention provides a method for preventing the reduction of at least one halogen substituted aromatic ring of an aromatic compound, while allowing the reduction of...
|
|
WO/2005/063680A1 |
The present invention provides a process for the preparation of arylamines comprises reacting aryl halide and aryl amine/heterocyclic amine. The said process is carried out in the presence of a solvent, catalyst and a base.
|
|
WO/2005/063848A1 |
A modified polyol having alkoxylation and amine capping units, uses of the modified polyol having alkoxylation and amine capping units, and leaning compositions having the modified polyol having alkoxylation and amine capping units.
|
|
WO/2005/063729A1 |
The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, whic...
|
|
WO/2005/063671A1 |
Ether derivatives which have excellent immunosuppressive activity; and a medicinal composition containing as an active ingredient a pharmacologically acceptable salt of any of the derivatives. They are a compound represented by the gener...
|
|
WO/2005/063222A1 |
An Hsp90 family protein inhibitor which contains as an active ingredient a benzene derivative represented by the following general formula (I), a prodrug thereof, or a pharmacologically acceptable salt of either.
|
|
WO/2005/063773A1 |
Disclosed is an ionic liquid which is composed of at least one anion selected from the group consisting of [BF3(CnF2n+1)]- (wherein n is 2, 3 or 4) and at least one organic ammonium ion.
|
|
WO/2005/061431A1 |
The invention relates to a method of obtaining tolterodine. The inventive method consists in: reacting a compound having formula (II), wherein R is a hydroxyl protective group and the asterisk indicates an asymmetric carbon atom, with di...
|
|
WO/2005/058796A2 |
A process for preparing venlafaxine in a high yield as well as processes for producing venlafaxine hydrochloride of form I having a very high polymorphic purity are described.
|
|
WO/2005/056516A1 |
The present invention relates to novel compounds corresponding to the general formula (I) below: to compositions containing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine, or alterna...
|
|
WO/2005/056499A2 |
Amphiphilic oligo(p-phenylene vinylene) compounds and methods of use en route to self-assembled composites and device fabrication.
|
|
WO/2005/051889A1 |
The invention relates to novel m-diaminobenzoles of formula (I), to the use thereof in colouring agents, and to oxidation hair dyes containing said m-diaminobenzoles.
|
|
WO/2005/051888A2 |
The invention relates to compounds of the formula (I) in which: i and j=1; R1 is in position 3 or 4 on the phenyl ring and represents a cyano group, an alkoxy group substituted by halogen, a thioalkyl group, an alkylcarbonyl group or an ...
|
|
WO/2005/049560A2 |
A process for the preparation of anti-depressant, compound of formula (I) or its pharmaceutically acceptable salts said process comprising reducing compound of formula (IIa) (wherein R is CONMe2) with sodium bis(2-methoxyethoxy) aluminiu...
|
|
WO/2005/047233A1 |
Compounds of formula (I), wherein Q is a group Q1, Q2, Q3, Q4, Q5, Q6, Q7 or Q8; A is a bridging member A1, A2, A3, A4 or A5 wherein the bridging members A1 to A5 are linked to the group Q at the end carrying the oxygen atom; B either is...
|
|
WO/2005/046568A2 |
Metoprolol manufacturing process with optimized reaction temperatures and reactant molar ratios, to avoid the manufacture of excessive epoxide intermediates, thus avoiding the need for purification of epoxide intermediates, thus achievin...
|
|
WO/2005/047249A1 |
The present invention relates to compounds which are CCR-5 receptor antagonists of the general formula (I) wherein R1, R2, R3, R4, Ra, Rb, Rc, Rd, X, m and n are as defined herein. The invention further comprises pharmaceutical compositi...
|
|
WO/2005/044787A1 |
Compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective β2-adrenoreceptor agonist is indicated, for example ...
|
|
WO/2005/042466A1 |
Disclosed is a quaternary ammonium salt represented by the following general formula: (1) (wherein R1 and R2 may be the same or different and represent a C1-4 alkyl group; R1 and R2 may form a saturated heterocycle together with nitrogen...
|
|
WO/2005/042467A1 |
The present invention provides novel quaternary amino-functional chalcone derivatives and analogues exhibiting interesting antibacterial activity. The compounds have the general formula (Y1)m-Ar1(X1)-C(=O)Var2(X2)-(Y2)p (I), wherein V de...
|
|
WO2004087061B1 |
A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for mol...
|
|
WO/2005/042465A1 |
This invention relates to novel o-substituted-naphthyloxy-amino alkanes, their preparation and use as antihyperglycemic agents and for the treatment and prevention of cardiovascular disorders (CVS) such as lipid-lowering effects.
|
|
WO/2005/040104A1 |
The present invention relates to novel hypolipidemic, antiobesity, hypocholesterolemic and antidiabetic compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general formula (I), their stereoi...
|
|
WO/2005/040102A2 |
The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar1” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may opti...
|
|
WO/2005/040103A1 |
Compounds of formula (I), and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective β2-adrenoreceptor agonist is indicated, for example...
|
|
WO/2005/037810A2 |
The invention relates to a compound of formula (I), wherein n ranges from 1 to 6, A is aryl such as phenyl or naphtyle, or monocyclic heteroaryl such as thienyl, furyl or pyrrolyl; aryl or heteroaryl being substituted, if necessary; B is...
|
|
WO/2005/036275A1 |
An electrophotographic photoreceptor that excels in not only electrical properties, such as sensitivity and photoresponse properties, but also abrasion resistance duration and that can prevent formation of flaw and density unevenness in ...
|
|
WO2004110364A9 |
The current invention provides novel thiotungstate derivatives, methods of making novel thiotungstate derivatives, pharmaceutical compositions of novel thiotungstate derivatives, methods of using novel thiotungstate derivatives to treat ...
|
|
WO/2005/028457A1 |
The present invention discloses a process for the preparation of quetiapine, which comprises the reaction of dibenzo[b,f][1,4]thiazepin-11-ylamine with a compound of the general formula (II) as well as novel intermediates in the process.
|
|
WO/2005/025555A2 |
The invention provides novel β2 adrenergic receptor agonist compounds of formula (I): wherein R1 - R13 and w have any of the values described in the specification. The invention also provides combinations of such compounds and other the...
|
|
WO/2005/023744A2 |
The present invention provides compounds useful in inhibiting protein kinase B (PKB/Akt). Compositions comprising such compounds and their use are also provided.
|
|
WO/2005/019164A2 |
The present invention relates to a novel process for the preparation of phenethanolamine derivatives, which process comprises the step of reacting a compound of formula RO(CH2)nBRaRb with a compound of formula (II).
|
|
WO/2005/016862A1 |
A compound represented by the formula (I)[In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting car...
|
|
WO/2005/016865A1 |
The invention provides gamma hydroxy primary carbamate functional compounds, film-forming compositions comprising such compounds and methods of making the same. The film-forming compositions disclosed herein comprise (I) a gamma hydroxy ...
|
|
WO/2005/014525A2 |
The invention is directed to a bi-aryl compound having a unique immunomodulating activity, a process for a preparation thereof, a pharmaceutical composition containing the same, and a method of preventing or treating disorders or disease...
|
|
WO/2005/012227A2 |
The present invention relates to processes for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol
of Formula I, which is a metabolite of tolterodine.
|
|
WO/2005/012221A1 |
A compound represented by the general formula (I): (wherein rings A, B, and D each independently represents an optionally substituted cyclic group; W represents a spacer whose main chain has 1 to 8 atoms; X represents a spacer whose main...
|
|
WO/2005/007603A2 |
The present invention is related to new derivatives of Combretastatin, of Formula (I) obtained by total synthesis. The strategy developed for each of the compounds is to i) replace a halogen (i.e. fluorine atom) to hydrogen on olefinic b...
|
|
WO/2005/007614A1 |
The invention includes compounds of formula (I), pharmaceutically acceptable salts thereof, compositions containing compounds of formula (I), methods of inhibiting at least one monoamine oxidase using a compound of formula (I), and metho...
|
|
WO/2005/007615A1 |
Disclosed are 2-(amino or substituted amino)-5-(substituted oxymethyl)-phenol compounds according to the Formula (I). Also, compositions for the oxidative dyeing of keratin fibers, comprising a medium suitable for dyeing and a compound o...
|
|
WO/2005/000775A2 |
The present invention is directed to novel cyclohexyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and diseases mediated by an estrogen receptor.
|
|
WO/2005/000795A2 |
This invention relates to aniline derived non-steroidal compounds that are or are believed to be modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of suc...
|
|
WO/2005/000788A1 |
The invention relates to a method for dehydrating substituted 4-dimethylamino-2-aryl-butan-2-ol compounds and to methods for producing substituted dimethyl-(3-aryl-butyl)-amine compounds by means of heterogeneous catalysis.
|
|
WO/2004/112478A1 |
Compounds of the formula: Rl R2N-CH2-CHO[(AO)m1 R4]-CH2-OR3 where Rl is alkoxylated polyhydroxy hydrocarbyl; R2 is as defined for Rl, or hydrocarbyl, particularly alkyl or alkoxyalkyl, alkoxylated hydroxyalkyl, or a group: -CH2-CHO[(AO)m...
|
